Innate and Non-Classical Immune Cells in Cancer Immunotherapy
Organizer(s): Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. LanierDate: March 24 - 28, 2019
Location: Keystone Resort, Keystone, CO, USA
Immunotherapy has revolutionized the treatment of many cancer types over the past five years. T cell checkpoint inhibitors have led the way and are the focus of most immunotherapy trials. However innate and non-classical T cells contribute extensively to the tumor infiltrate and significantly impact on the tumor immune response in both the tumor microenvironment and in circulation. This symposium aims to bring together academic and industry opinion leaders in the fields of innate immune cells, natural killer cells, tumor microenvironment, tumor immune suppression, novel immunotherapeutic strategies and clinical cancer immunotherapy to define the next wave of immunotherapy breakthroughs that reach beyond the current T cell checkpoints. The conference offers a unique opportunity for an audience of diverse immunology and cancer research backgrounds to come together and share cutting edge insights into cancer immunology and rational approaches for therapeutic intervention that could be used as be standalone therapy or in combination with T cell checkpoint therapies. A key aim is to bring together experts with complementary interest in cancer immunotherapy that would not normally be drawn to common symposia and foster new dynamic collaborations to advance our understanding of tumor immunity.
Scholarship Deadline: December 4 2018
Discounted Abstract Deadline: December 4 2018
Abstract Deadline: December 13 2018
Discounted Registration Deadline: January 23 2019
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Bristol-Myers Squibb Company
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA236119-01
Funding for this conference was made possible (in part) by 1R13CA236119-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.